Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Imiquimod 5% cream Clear all
Active, not recruiting Phase 1 Interventional

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

NCT01421017
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions
Radiation, Imiquimod, Cyclophosphamide
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 1 Interventional

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

NCT00865644
View directory record Official record
Conditions
Neurofibromatosis Type 1, Cutaneous Neurofibromas
Interventions
Imiquimod 5% Cream
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Results available

Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses

NCT00774787
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod 5% cream
Drug
Lead sponsor
Rigel Dermatology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
St. Petersburg, Florida • Henderson, Nevada • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

NCT00948428
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod, Aldara™, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Hot Springs, Arkansas • Fresno, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 5, 2026, 2:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

1-Year Follow up to the 1473-IMIQ Study

NCT00114023
View directory record Official record
Conditions
Keratosis
Interventions
Imiquimod 5% cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2007 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Early Phase 1 Interventional Results available

Neoadjuvant Imiquimod Immunotherapy for Oral Cancer

NCT04883645
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma
Interventions
Imiquimod 5% Cream
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

NCT02482428
View directory record Official record
Conditions
External Genital Warts
Interventions
Investigational Treatment, Aldara
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 5, 2026, 2:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

NCT02224599
View directory record Official record
Conditions
Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer
Interventions
TAPA-pulsed DC vaccine, Cyclophosphamide Pill, Imiquimod Topical Cream
Biological · Drug
Lead sponsor
Kiromic BioPharma Inc.
Industry
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 5, 2026, 2:18 PM EDT
Terminated Not applicable Interventional Results available

Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

NCT00470392
View directory record Official record
Conditions
Psoriasis
Interventions
Imiquimod, Clobetasol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

NCT00273910
View directory record Official record
Conditions
High-Risk Melanoma
Interventions
gp100:209-217 (210M), Montanide ISA-51, Imiquimod
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

NCT00335179
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aldara (imiquimod 5% cream), Vehicle cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2010 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunologic Profile of Chronically Photodamaged Skin

NCT02889159
View directory record Official record
Conditions
Photoaged Skin, Normal Skin
Interventions
Candida albicans antigen, histamine phosphate, imiquimod 5% cream, Tape Stripping
Biological · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648
View directory record Official record
Conditions
Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 5, 2026, 2:18 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC

NCT03370406
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
5-fluorouracil, Calcipotriene
Drug
Lead sponsor
Melissa Pugliano-Mauro
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 5, 2026, 2:18 PM EDT
Terminated Phase 2 Interventional Results available

Imiquimod for Preventing Keloid Recurrence

NCT03760250
View directory record Official record
Conditions
Keloid
Interventions
Imiquimod 5% cream
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 5, 2026, 2:18 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Basal Cell Carcinoma Chemoprevention Trial

NCT05212246
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
5% Imiquimod cream, Placebo Vehicle Control Cream
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 4 Interventional

Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

NCT06840470
View directory record Official record
Conditions
Sebaceous Hyperplasia
Interventions
Imiquimod 5% Topical Cream
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 5, 2026, 2:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

Topical Imiquimod Treatment of Oral Dysplasia

NCT07210775
View directory record Official record
Conditions
Oral Dysplasia, Leukoplakia Oral, Leukoplakia
Interventions
Imiquimod (topical use)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 5, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal

NCT00638651
View directory record Official record
Conditions
Healthy
Interventions
1064 nm Nd:YAG laser, Imiquimod, 5% cream
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 5, 2026, 2:18 PM EDT